Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as ...

The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

Beyond the surface of your skin, eczema, psoriasis and more can majorly impact your self image and intimate relationships.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the povorcitinib/povo Phase3 results in moderate to severe hidradenitis ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.

MoonLake Immunotherapeutics (MLTX) stock gains as RBC Capital Markets starts with outperform rating, citing $2B+ sales ...

US biotech Incyte (Nasdaq: INCY) has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 ...

The S&P 500 edged up 0.6% on Monday, March 17, after a report showed retail sales recovered in February but fell short of ...